Medical evaluation first
Health history, medications, goals, contraindications and the evidence behind a proposed protocol are reviewed before prescription.
Peptide therapy is a fast-changing area of medicine. Skin Works offers consultation-led programs for recovery, body composition, skin support, cognitive goals, longevity and sexual wellness, with the specific compound, formulation and pharmacy availability confirmed by the medical team before treatment.
Prescription required. Many peptide uses are investigational or off-label. Availability can change with federal/state rules and pharmacy sourcing.

Peptides are short chains of amino acids involved in many signaling pathways in the body. That does not mean every marketed peptide has proven clinical benefit. The important questions are which compound is being considered, what evidence exists for the goal, whether the formulation is legally available, and whether it makes sense for the individual.
Health history, medications, goals, contraindications and the evidence behind a proposed protocol are reviewed before prescription.
Compounding rules and pharmacy availability can change. The website does not override current federal or state requirements.
An FDA-approved brand indication is not the same as saying every compounded version or wellness use is FDA-approved.
If a protocol is prescribed, the team remains available for administration guidance, follow-up questions and appropriate reassessment.
Many peptides marketed in wellness settings are not FDA-approved drugs. Compounded medications are also not FDA-approved simply because they are made by a licensed pharmacy.
Program names and pricing below reflect the clinic menu supplied for this page. Actual availability, formulation, pharmacy source and prescription are confirmed at the time of consultation and may change. FDA-approved tesamorelin and bremelanotide products also have narrow labeled indications; other uses should not be represented as FDA-approved.

Programs discussed for soft-tissue recovery, post-procedure support and related goals. These compounds are not FDA-approved for these wellness uses, and availability can change.
A clinic-defined compounded blend combining BPC-157 and a TB-500-related peptide for patients exploring recovery support. Both components are investigational for these uses and are not FDA-approved drugs.
Discuss this program →BPC-157 is an investigational peptide frequently discussed in recovery settings. Human evidence remains limited, and it is not FDA-approved. Form, prescription and availability must be confirmed by the medical team.
Discuss this program →TB-500-related peptides are investigational and not FDA-approved. The clinic may discuss them for selected recovery goals only after reviewing candidacy, evidence, risks and current pharmacy availability.
Discuss this program →
Options in this category act on or relate to growth-hormone signaling. Candidacy, laboratory review, risks and regulatory status differ substantially by compound.
A compounded growth-hormone-axis combination discussed for selected wellness goals. Neither compound is FDA-approved for the broad anti-aging or body-composition claims commonly made online, and current compounding status should be confirmed.
Discuss this program →Tesamorelin is the active ingredient in Egrifta, an FDA-approved drug for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA-approved as a general weight-loss drug. Any use outside the approved indication requires separate medical judgment.
Discuss this program →AOD-9604 is an investigational growth-hormone fragment marketed for body-composition goals. It is not FDA-approved, and evidence for routine weight-management use remains limited.
Discuss this program →Sermorelin is a growth-hormone-releasing hormone analogue used in some compounded protocols. Current formulation, clinical rationale and pharmacy availability are reviewed individually before prescription.
Discuss this program →
Peptide-based programs discussed alongside aesthetic care. Formulation matters: injectable and topical/non-injectable products can have different regulatory considerations.
A clinic-defined blend combining GHK-Cu, BPC-157 and a TB-500-related peptide. The components have different evidence and regulatory profiles, so formulation and availability are confirmed at consultation.
Discuss this program →GHK-Cu is a naturally occurring copper-binding peptide studied in skin and wound biology. Topical/non-injectable and injectable formulations have different regulatory considerations; formulation availability is confirmed by the clinic.
Discuss this program →
Semax and Selank are investigational in the United States and are not FDA-approved drugs. Any use requires individualized medical review and confirmation of legal pharmacy availability.
Semax is an investigational peptide studied primarily outside the United States. It is not FDA-approved in the U.S. Claims around cognition and neuroprotection remain investigational.
Discuss this program →Selank is an investigational peptide studied primarily outside the United States. It is not FDA-approved in the U.S. and should not be presented as a proven replacement for approved anxiety or mood treatments.
Discuss this program →A clinic-defined combination of Semax and Selank. Both are investigational in the United States, so evidence, candidacy and current pharmacy availability are reviewed before any prescription.
Discuss this program →
These programs include investigational compounds with evolving evidence and compounding status. The website should be a starting point, not a substitute for a medical and regulatory review.
A proprietary clinic-defined blend positioned around metabolic and inflammatory goals. Composition, medical rationale, price and current availability are reviewed directly with the provider at consultation.
Discuss this program →MOTS-c is a mitochondrial-derived peptide under active research. It is not FDA-approved for metabolic optimization, weight loss or longevity, and human clinical evidence remains limited.
Discuss this program →Epitalon (Epithalon) is an investigational peptide associated with longevity research. It is not FDA-approved in the United States, and claims involving telomeres or lifespan should be considered investigational.
Discuss this program →Thymosin alpha-1 has been studied internationally for immune-related indications but is not an FDA-approved drug in the United States. Use and availability require individualized medical review.
Discuss this program →
Bremelanotide is the active ingredient in FDA-approved Vyleesi, but the FDA-approved indication is specific. Other uses are not the same as the labeled Vyleesi indication.
Bremelanotide is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Vyleesi is not FDA-approved for men, postmenopausal women, performance enhancement, or general libido optimization; other use is outside the labeled indication.
Discuss this program →The consultation is where goals are translated into a real clinical decision, including whether peptide therapy should be used at all.
Discuss your goals, health history, medications and the specific program you are interested in.
Your medical provider determines candidacy, current legal/pharmacy availability and whether a prescription is appropriate.
If prescribed, you receive current pricing, administration guidance and a follow-up plan appropriate to the medication and goal.
Peptide therapy should be discussed compound by compound rather than treated as one single category of medicine.
Meet with the Skin Works medical team, review what you are trying to improve, and get a clear answer about candidacy, current options, pricing and whether peptide therapy makes sense for you.
Medical disclaimer: This page is informational and does not constitute medical advice or a prescription. Program availability, formulation, price and pharmacy sourcing may change. Many peptide compounds and wellness uses described on the market are not FDA-approved. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing in the same way as FDA-approved drugs.